Danaher Corporation $DHR Stock Sold by Impax Asset Management Group plc

Impax Asset Management Group plc cut its stake in shares of Danaher Corporation (NYSE:DHR – Free Report) by 87.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 12,203 shares of the conglomerate’s stock after selling 85,834 shares during the quarter. Impax Asset Management Group plc’s holdings in Danaher were worth $2,704,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Prime Capital Investment Advisors LLC grew its holdings in Danaher by 0.5% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock worth $2,039,000 after acquiring an additional 45 shares during the period. Essential Investment Partners LLC raised its position in shares of Danaher by 34.6% in the 3rd quarter. Essential Investment Partners LLC now owns 175 shares of the conglomerate’s stock worth $39,000 after acquiring an additional 45 shares in the last quarter. Montis Financial LLC raised its position in shares of Danaher by 2.3% in the 3rd quarter. Montis Financial LLC now owns 2,020 shares of the conglomerate’s stock worth $448,000 after acquiring an additional 46 shares in the last quarter. Covestor Ltd lifted its stake in shares of Danaher by 28.3% in the 3rd quarter. Covestor Ltd now owns 213 shares of the conglomerate’s stock valued at $47,000 after purchasing an additional 47 shares during the period. Finally, Veery Capital LLC lifted its stake in shares of Danaher by 3.1% in the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after purchasing an additional 48 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CAO Christopher Bouda sold 7,598 shares of Danaher stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total value of $1,782,186.88. Following the completion of the sale, the chief accounting officer owned 9,107 shares of the company’s stock, valued at approximately $2,136,137.92. This trade represents a 45.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gregory M. Milosevich sold 2,100 shares of the business’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $230.62, for a total transaction of $484,302.00. Following the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $5,158,277.54. This trade represents a 8.58% decrease in their position. The SEC filing for this sale provides additional information. 10.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

DHR has been the topic of several research analyst reports. Citigroup upped their target price on Danaher from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Morgan Stanley lifted their target price on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Barclays boosted their price target on Danaher from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Robert W. Baird increased their price target on Danaher from $246.00 to $254.00 and gave the stock an “outperform” rating in a report on Thursday, October 22nd. Finally, Wells Fargo & Company reduced their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Eighteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $242.91.

Read Our Latest Research Report on Danaher

Danaher Stock Performance

Shares of Danaher stock opened at $228.40 on Thursday. The business has a 50-day simple moving average of $223.88 and a 200 day simple moving average of $201.62. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.29. The firm has a market capitalization of $160.68 billion, a price-to-earnings ratio of 37.38, a PEG ratio of 2.84 and a beta of 0.76.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.92 by $0.19. The business had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The company’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.89 earnings per share. On average, research analysts anticipate that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a dividend of $0.40 per share. The ex-dividend date was Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s payout ratio is currently 26.19%.

Danaher Company Profile

(Free Report)

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.